If approved, LEQEMBI would become the only subcutaneous treatment for Alzheimer's that can be administered at home, with weekly dosing intended to maintain clinical benefits after an initial ...

There were seven variables associated with adherence to cardiovascular medications from the univariable analyses as shown in table 2. The following variables ... For the other classes, 98.0% of the ...

Patient demographic data, such as average or median age, percentage of female participants, and baseline body mass index ... therapy (Table 3). The study by Zuo FT and colleagues suggested that in ...

A summary of this comparison can be found in Table 1. A growing number of studies ... also require special considerations for drug dosing. In a retrospective study conducted in patients with high body ...

The use of aspirin and non-aspirin NSAIDs should be noted ... Examination usually contributes little but may reveal a relevant abdominal mass or cutaneous signs of rare causes of GI blood loss (eg, ...

20 – 22 The objective of the current phase 2 study was to evaluate the efficacy and safety of the novel synergistic drug candidate CRx-102 compared to placebo in patients with HOA over a 6-week dosing ...

Peak plasma concentrations of pravastatin are reached 1-1.5 hours after dosing and the elimination half-life is approximately 77 hours. After oral administration, aspirin is rapidly hydrolyzed in ...

Approximately 48% of people think that the benefits of taking low-dose aspirin every day to lower their risk of heart attack or stroke outweigh the risks, but they’re wrong, according to a survey from ...

For years, healthy older adults were advised by doctors to take a low-dose aspirin daily as a way to reduce the risk of heart ...

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...